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1. Introduction
  According to WHO, 25% of global adult population are suffering 
from hypertension which has been reported to be a common risk 
factor for the development of left ventricular hypertrophy (LVH)
[1-3]. For patients with essential hypertension, LVH can stimulate the 
risk of cardiovascular disease and even cause death of patients[4,5]. 
Nitric oxide (NO) is a signaling molecule synthesized by endothelial 
nitric oxide synthase (eNOS) and this compound is considered 
to have cardioprotective effects by being responsible for multiple 
functions such as the regulation of vascular tone and relevant gene 
expression[6]. As reported, eNOS/NO signaling pathway is related 
to many cardiovascular diseases including myocardial hypertrophy. 
It is found that angiotensin type 栻 (AT2) receptor can be activated 
by the expression of cardiac eNOS and therefore produce an 
antihypertrophic effect[7]. In the diabetic heart, the maintenance of 
Akt/eNOS/NO signaling is suggested to attenuate cardiac diastolic 
dysfunction[8]. Polhemus et al reported that the increase in the 
phosphorylation of eNOS and the bioavailability of NO could 
improve vascular density to attenuate left ventricular remodeling in 
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H2S-treated hearts[9]. Profilin-1, having a molecular weight of 12-15 
kD, belongs to the family of actin-binding proteins. The activation 
of a hypertrophic signaling cascade by this protein can regulate 
actin polymerization and cytoskeleton remodeling[10]. Profilin-1 
has been found to function in eNOS uncoupling by activating Akt/
Erk signaling pathway[11] and its molecular expression and protein 
phosphorylation exert a regulatory mechanism in the development 
of cardiovascular diseases[12]. As mentioned above, Profilin-1 
and eNOS/NO signaling pathway are related with cardiovascular 
diseases, while the information in this regard is elusive in 
patients with essential hypertrophy and hypertension. In this 
study, the constructed adenovirus vectors were used to induce the 
overexpression or silence of Profilin-1 in spontaneously hypertensive 
rats. The relationship between Profilin-1 and eNOS/NO pathway 
and their role in myocardial hypertrophy were analyzed and this 
study may provide reference for the therapy of this disease through 
possible Profilin-1 regulation.
2. Materials and methods
2.1. Materials
  Experimental animals: Spontaneously hypertensive rats (SHR) and 
Wistar-Kyoto rats (WKY) with all aged four weeks were used in 
the present study. The SPF male rats were purchased from Yaoming 
Kangde new drug development co., LTD. Shanghai [SYXK (Hu) 
2010-0102]. All rats were acclimated at room temperature of (23±1) 曟
with a constant diurnal rhythm and well ventilation. Prior to 
experiments initiation, an acclimation of one week was allowed.
  Reagents: rhIL-2 (Shenyang 3SBio Inc.); RPMI-1640 and M19 
medium (Gibco, USA); fetal bovine serum (Beijing Solarbio Science 
& Technology Co., Ltd., China); NKC culture kit (Jiangsu Vanvo 
Bio-medical Technology Co., Ltd.); antibody CD31 and VEGF 
(Invitrogen, USA); DNA marker (Promega, USA).
Instruments: Synergy 2 multimode reader (Biotek, USA); SHELLAB 
CO2 incubator (SHELLAB, USA); Stratedigmflow cytometry 
(Stratedigm, USA); Biometra gradient PCR amplifier (Biometra, 
Germany); rodent ventilator (Kent, USA); DYY-2C electrophoresis 
apparatus (Beijing Liuyi Instrument Plant, China); BioSpectrum- 
UVP Gel Imaging System (UVP, USA).
2.2. Experimental procedures
  Adenovirus vectors of Profilin-1 silence (pAd-miR-profilin-1) 
and overexpression (Ad-profilin-1-IRES-EGFP) were established 
respectively. 
  SHR rats of 60 were randomly divided into three groups (20 rats 
in each group) as following: SHR-C (treated with control vector), 
SHR-I (treated with pAd-miR-profilin-1) and SHR-H (treated with 
Ad-profilin-1-IRES-EGFP). At the same time, 20 WKY rats were 
treated with control vector and named WKY-C group. All treatments 
were conducted by tail intravenous injection at a dose of 3×109 
PFU/rat, which was done again at sixth week during the experiment 
of 12 weeks (ie. rats grew from 5 to 17 weeks old). 
2.3. Sample collection
  After the experiment of 12 weeks, all rats were rendered 
unconscious with 2% isoflurane. Blood sample was then withdrawn 
from hepatic portal vein and centrifuged for 10 min at 4 曟 and 
3 000 g. Supernatants were stored at -80 曟 until the analysis of NO 
content. The hearts were were excised and weighted (heart weight, 
HW). Then, left free ventricular wall and interventricular septum 
were excised and weighted to obtain the left ventricular weight 
(LVW). The left ventricular long axis (LVLA) from the atrial valve 
to apex cordis was measured with a vernier caliper.
  After measurement, left ventricle sample was excised, rinsed with 
ice-cold saline and dried with blotting paper. After that, the sampled 
was placed into a microtube, flash frozen in liquid nitrogen and 
finally stored at -80 曟 for the determination of the expression of 
Profilin 1, eNOS and caveolin 3 and the phosphorylation of eNOS 
(P-eNOS).
2.4. Determination of NO in blood and myocardium
  Frozen myocardial tissue was powdered with mortar and 
pestle under liquid nitrogen and a certain amount of powder was 
homogenized in 9 volumes of 0.85% saline. After centrifugation 
of 10 min at 1 000 g and 4 曟, supernatants were collected for the 
determination of NO content in myocardium with commercial NO 
test kits (nitrate reductase method) according to the manufacturers’ 
instructions (Nanjing Jiancheng Bioengineering Institute, China). 
Table 1 
Sequences of Profilin 1, eNOS, Caveolin 3 and 毬-actin primers.
Genes Sense primer Reverse primer
Profilin 1 5’-ATGCAGGGATGATGTTCTGG-3’ 5’-GTGCAAAAGCCAAAGGGAG-3’
eNOS 5’-TGGGCAGCATCACCTACGATA-3’ 5’-GGAACCACTCCTTTTGATCGAGTTAT-3’
Caveolin 3 5’-GCTGCACCAGGGAACACTAT-3’ 5’-CCCTATTTATGCCCAGCAAA-3’
毬-actin 5’-CTCCATCCTGGCCTCGCTGT-3’ 5’-GCTGTCACCTTCACCGTTCC-3’
PCR system (20 毺L): 2.5×master solution 8 毺L, 20×SYBR Green 1 毺L, sense (10 毺M) and reverse primers (10 毺M) 0.25 mL respectively, 
cDNA 1.5 毺L, ddH2O 9 毺L.
PCR amplifying conditions: 95 曟 1 min; 95 曟 5 s, 58 曟 15 s, 68 曟 20 s (containing 35 cycles); 65 曟 7 min, 4 曟.
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The absorbance of final reaction system at 550 nm was read and 
used to calculate NO concentration (毺mol/L). Blood NO content 
was also measured with the same kit. 
2.5. Determination of mRNA levels of Profilin 1, eNOS and 
caveolin 3 
  The mRNA levels of Profilin 1, eNOS and caveolin 3 were 
determined with the RT-PCR method. Myocardium tissue was 
powdered under liquid nitrogen and mixed with Trizol reagent. 
Total RNA was extracted using a commercial kit (Invitrogen, USA) 
followed by the detection of RNA content (A260) and purity (A260/ 
A280).
  Total RNA of 1 毺g was reverse transcribed into the first strand of 
cDNA and the product was PCR amplified after addition of Profilin 
1, eNOS and caveolin 3 primers respectively. 毬-actin was used as 
the reference gene. Primers sequences were listed in Table 1. The 
amplification results were analyzed using the2-△△Ct method.
2.6. Determination of mRNA levels of Profilin 1, eNOS, 
P-eNOS and caveolin 3
  Western-blot method was applied for the determination of protein 
levels of Profilin 1, eNOS, P-eNOS and caveolin 3. Total protein was 
extracted from 50 mg myocardium tissue after addition of 500 毺L 
RIPA. After 20 min on ice, the mixture was centrifuged for 10 min 
at 12 000 g and 4 曟. Collected supernatants were mixed with buffer 
solution, boiled for 5 min and stored at -20 曟.
  Total protein concentration was measured with the Bicinchoninic 
Acid (BCA) method (562 nm) using a commercial kit (Sangon 
Biotech (Shanghai) Co.,Ltd., China). Sample protein was 
separated by sodium dodecyl sulfate (SDS)-polyacrylamide gels 
and transferred onto polyvinylidene fluoride (PVDF) membranes 
followed by blocking with skimmed milk powder. After incubation 
overnight at 4 曟 with corresponding primary antibodies of Profilin 
1, eNOS, P-eNOS and caveolin 3, membranes were washed 
with 1×TBST. Then membranes were mixed with corresponding 
secondary antibodies and incubated at room temperature for 1 h. 
After another washing with 1×TBST, the color reagent of ECL-
plus was added and protein levels was analyzed with Quantity One 
biological gel electrophoresis image analysis system. Using 毬-actin 
as the control, the relative optical density was used to represent the 
relative protein level of Profilin 1, eNOS and caveolin 3, while for 
P-eNOS, total protein level was used as the control. All primary 
and secondary antibodies were purchased from Beijing Zhongshan 
Golden Bridge Biotechnology Co., Ltd.
2.7. Statistical analysis
  Data in the present study were expressed as mean±SD and analyzed 
with SPSS 13.0 software. Differences between treatments were 
determined using Student’s t-test. P-values<0.05 were considered 
statistically significant for all variance tests.
3. Results
3.1. Effects of Profilin-1 on LVW/HW and LVLA
  The LVW/HW and LVLA were used as two indicators to reflect 
myocardial hypertrophy, which were shown in table 1. With respect 
to LVW/HW, SHR-C group (0.79±0.03) was statistically higher than 
WKY-C group (0.63±0.04) (t=0.08, P<0.01) and SHR-I group (0.68 
±0.05) (t=0.05, P<0.05) and lower than SHR-H group (0.93±0.03) 
(t=0.07, P<0.05). A similar difference between treatments was also 
observed in LVLA. The SHR-C group was significantly higher in 
LVLA (11.82±0.58) than WKY-C group (9.13±0.49) (t=1.28, P< 
0.01) and SHR-I group (9.52±0.51) (t=1.09, P<0.01) and lower than 
SHR-H group (14.17±0.69) (t=1.16, P<0.01).
3.2. Effects of Profilin 1 on NO content in myocardium and 
blood
  As shown in Figure 1A, WKY-C group had a higher blood NO 
content (31.50±7.52) than SHR-C group (18.63±6.23) and the 
difference was significant (t=6.23, P<0.01). However, no significant 
difference was detected between SHR-C group and SHR-I group 
(17.52±5.65) or SHR-H group (16.47±5.12) (P>0.05).
  For NO content in the myocardium (Figure 1B), WKY-C group 
(3.67±0.19) was significantly higher than SHR-C group (2.71±0.17) 
(t=0.43, P<0.05). Compared to the NO level of SHR-C group, SHR-I 
group (3.45±0.25) was significantly higher (t=0.35, P<0.05) while 
Table 2 
Effects of Profilin 1 on LVW/HW and LVLA (n=20).
Index Treatments Treatments t value P value
LCW/HW SHR-C 0.79±0.03 WKY-C   0.63±0.04 0.08 0.003
SHR-I   0.68±0.05 0.05 0.021
SHR-H   0.93±0.03 0.07 0.015
LVLA (mm) SHR-C 11.82±0.58 WKY-C   9.13±0.49 1.28 0.005
SHR-I   9.52±0.51 1.09 0.000
SHR-H 14.17±0.69 1.16 0.018
Note: t and P values indicate the difference between the treatment in the same row and SHR-C group. 
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Figure 1. Content of NO in serum (A) and cardiac muscle (B) of different 
treatments.
Note: “*” indicates a significant difference compared to SHR-C group 
(P<0.05), while “**” indicates an extremely significant difference (P<0.01).
3.3. Effects of Profilin 1 on mRNA levels of related genes in 
myocardium
  Figure 2 shows that WKY-C group was lower in Profilin 1 mRNA 
level compared to SHR-C group and a significant difference was 
detected (t=0.76, P<0.01). The Profilin 1 mRNA level was reduced 
in SHR-I group (t=0.41, P<0.05) and elevated in SHR-H group (t= 
0.38, P<0.05) compared to SHR-C group.
  With regard to eNOS mRNA level, no significant difference was 
detected between treatments (P>0.05).
  Caveolin mRNA expression of SHR-C group was reduced to 
51.42% of WKY-C group and a statistical difference was detected 
(t=0.24, P<0.05). In comparison with SHR-C group, caveolin 
expression was significantly elevated in SHR-I group (t=0.16, P< 
0.05) and reduced in SHR-H group (t=0.13, P<0.01).
3.4. Effects of Profilin 1 on protein levels of related genes in 
myocardium
  Figure 3 shows the protein levels of Profilin 1, eNOS, P-eNOS 
and Caveolin-3. WKY-C group showed a significantly lower protein 
level of Profilin 1 than SHR-C group (t=0.09, P<0.05), and SHR-C 
group was lower than SHR-H group (t=0.15, P<0.05) and higher 
than SHR-I group (t=0.13, P<0.01).
  With regard to eNOS protein level, no significant difference 
was observed between treatments (P>0.05). However, significant 
differences were observed between treatments in the P-eNOS protein 
level: it was higher in WKY-C group and SHR-I group but lower in 
SHR-H group when compared to that in SHR-C group.
  Compared to SHR-C group, the caveolin 3 protein level was 
elevated in WKY-C group and the difference was statistically 
significant (t=0.15, P<0.01). SHR-C group was significantly lower 
in caveolin 3 protein level than SHR-I group (t=0.09, P<0.01) and 
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Figure 2. mRNA expression levels of Profilin 1, eNOS and Caveolin-3 in 
different treatments.
Note: “*” indicates a significant difference compared to SHR-C group 















































Figure 3. Protein expression levels of Profilin-1, eNOS, P-eNOS and 
Caveolin-3 in different treatments.
Note: “*” indicates a significant difference compared to SHR-C group 
(P<0.05), while “**” indicates an extremely significant difference (P<0.01).
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4. Discussion
  Hypertension is a common chronic disease related with human 
health and also a cause of many diseases including cardiovascular 
diseases. eNOS/NO signaling pathway is reported to exert a 
protective effect on cardiovascular system by regulating NO level[6]. 
Profilin 1 is an important participator in the regulation of multiple 
signaling pathways and consequently influences the development of 
cardiovascular diseases[12,13]. In the present study, we explored the 
relationship between Profilin 1 and eNOS/NO signaling pathway and 
further studied the effect of silence and overexpression of Profilin 
1 on hypertensive cardial hypertrophy. This study aimed to provide 
reference for the potential value of Profilin 1 in hypertrophy therapy. 
4.1. Effects of Profilin 1 on eNOS/NO signaling pathway
  NO is a bioactive molecule involved in the regulation of blood 
pressure[14,15] and its release into vascular vessel can inhibit 
platelet and leukocyte adhesion to the vascular wall[6]. In the 
present study, we detected NO level in myocardium and blood 
of rats with Profilin 1 silence or overexpression. A significant 
change in NO level was only observed in myocardium of SHR 
rats, indicating that this gene might function locally in myocardial 
tissue rather than influence organismal NO level through systemic 
response. In cells, the elevation of eNOS activity and its product-
NO contribute to the elimination of reactive oxygen species (ROS)
[16] and the maintenance of vascular function[17]. According to 
the detection of eNOS mRNA and protein expression level, we 
found that overexpressed Profilin 1 could reduce eNOS activity 
and NO content in myocardium, resulting in a weaker capability 
of scavenging ROS[14] and a consequent declined protection effect 
to cardiovascular system. As a result, an enlarged LVW/HW and 
LVLA was observed in myocardium. In contrast, silencing Profilin 
1 activated eNOS activity and elevated NO level, which are believed 
to be good to stabilize blood pressure and therefore to attenuate 
myocardial hypertrophy.
  Caveolae are sacs with diameter of 50-100 nm which are formed 
by invagination of cell membranes and their principal components 
are caveolin, sphingolipid and cholesterol[18]. Caveolin plays a 
central role in extracellular signals enrichment and intracellular 
signals transduction[18]. As one of the three components of caveolin 
(i.e. caveolin 1, 2 and 3), caveolin 3 is only found in muscle and 
can interact with eNOS to regulate multiple signal transduction 
pathways[18,19]. The expression of caveolin 3 has been reported 
by many studies to be conducive to the attenuation of myocardial 
hypertrophy. Horikawa et al found that overexpression of caveolin 
3 could improve myocardial hypertrophy in transgenic mice by 
increasing the natriuretic peptide expression and signaling[20]. 
Feiner et al reported that the selective decrease in the expression 
of caveolin 3 could lead to left ventricular dysfunction[21]. In the 
present study, caveolin 3 expression and eNOS/NO pathway activity 
was lower in SHR rats than in WKY rats, while this situation was 
reversed by silencing Profilin 1. This suggests that Profilin 1 has an 
inhibitory effect on caveolin 3 expression, which may be due to that 
the disturbed actin polymerization influences caveolae function and 
structure and eNOS activity[18,19].
4.2. Relationship between Profilin 1 and myocardial 
hypertrophy
  The development of myocardial hypertrophy was regulated 
by many factors including Profilin 1[22]. The close relationship 
between Profilin 1 and eNOS/NO pathway is may be related with 
the role of the former in actin polymerization and cytoskeleton 
remodeling[10,23]. As an important actin binding protein, the normal 
expression of Profilin 1 can help maintain the structure and function 
of actin microfilaments, while dysfunctional Profilin 1 expression 
usually break the balance. The study of Caglayan et al demonstrated 
the role of Profilin 1 expression in atherosclerosis, making this 
gene become a potential target in disease treatment[24]. Zhong et al 
reported that the expression of Profilin 1 was elevated in aorta of 
SHR rats and telmisartan could inhibit its expression to attenuate 
aortic hypertrophy[25]. It was found in the present study that SHR rats 
possessed a higher value of LVW/HW and LVLA than WKY rats 
and correspondingly the former had a higher Profilin 1 expression 
level. Through overexpressing or silencing Profilin 1 in SHR rats, 
our study demonstrated the positive relationship between Profilin 
1 expression and hypertensive cardiac hypertrophy. According to 
our results, Profilin 1 silence significantly improved hypertensive 
cardiac hypertrophy, which provided further evidence that Profilin 
1 expression is not good to maintenance of cardiovascular structure 
and function.
  It should be noticed that no valid evidence could be provided 
concerning the role of Profilin 1 in the direct regulation of eNOS/NO 
pathway. In fact, genes like IL-18[19] and ACE2[10,11] also play a role 
in the development of myocardial hypertrophy. What’s more, how 
other factors related with Profilin 1 and eNOS/NO pathway influence 
hypertensive cardiac hypertrophy remains elusive. Accordingly, a 
further study is needed to find out the synergistic function of these 
factors in myocardial hypertrophy.
  As discussed above, Profilin 1 expression could inhibit the 
expression of caveolin 3 and the activity of eNOS/NO pathway, 
exerting a promotion effect to the development of hypertensive 
cardiac hypertrophy. However, this situation can be reversed 
by silencing Profilin 1 and myocardial hypertrophy is therefore 
improved. Results of this study not only enrich the study of the 
regulatory mechanisms of myocardial hypertrophy but also may be a 
scientific reference for its clinical therapy through silencing Profilin 1.
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